It remains healthcare providers telling consumers about it. We tried to innovate to reach the consumers more with things like provider mode, which now has 400,000 activated providers. We are trying to get those providers and make it even easier to activate them in their workflow. We continue to do marketing, albeit continue to do it as efficiently and effectively as we can, but those are the ways. You know, we’ll continue running marketing and continuing running our innovative product efforts, but we’re largely benefited by the brand and trust that we built. Relative to the second part of your question, which was just how the industry is evolving and budget dynamic. I think I would speak generally that the industry is always changing. We believe our network, you know our relationships with retail, with PBM, with pharma manufacturers is the strongest it’s been in our history.
When we look various entities in those channels, you know you mentioned spending budget for awareness, so €“ you know and one entity that would do that for example would be the pharma manufacturers. We believe that you know there are €“ on a long term basis the environment there is very good. We think that we will see strong growth this year in manufacturer solutions and glad to discuss some of this more. Hope that was helpful.
Eric Sheridan: Thank you.
Operator: Thank you. One moment for our next question. It will come from the line of Stephanie Davis with SVB Leerink. Your line is open.
Stephanie Davis : Hey guys! Thanks for taking my questions. Kind of on that same sort of manufacturer solutions question that we guys just have, how should we think about some of the blockbuster consumer drug releases, like and how would something like that factor into growth on the platform? Is that relatively small versus the larger base, so when will it be impactful for the year, or is that something that could be a larger impact there?
Trevor Bezdek: Yeah, thank you very much Stephanie. The pharma manufacturer business continues to grow at a fast clip. We grew about a 30% year-over-year despite the tough 4Q comp last year, and that rapid growth is because of the strength of the brand that I’ve been speaking about with consumers and with healthcare professionals and our deep relationship with healthcare professionals and manufacturers want to leverage that for access and awareness. And so we’re proud we have these relationships that we talked about last earning call. 19 of the top 20 manufacturers, and we’re continuing to grow into those accounts, adding more brand, adding. more other additional manufacturers outside of those top 20. So there’s a lot of progress there, a lot of good launches.
Those drugs you mentioned, those are great opportunities. They are places where we can really help on access and driving that awareness and effectively using the spend. But what I would highlight is, while the net total portion of our business will grow for the year significantly, and we think this will be the fastest growing area of our business, we don’t have significant concentration here. So we work with a lot of manufacturers on a lot of programs, so one program, two programs like you mentioned would not alone meaningfully change it. But we do see lots of opportunity here across a lot of products.
